Suntec Medical, Inc., 28F., No. 27-2, Sec. 2, Zhongzheng E. Rd., Tamsui Dist., New Taipei City 251, Taiwan.
Suntec Medical, Inc., 28F., No. 27-2, Sec. 2, Zhongzheng E. Rd., Tamsui Dist., New Taipei City 251, Taiwan; Suntec Medical, Inc, 4008 Blair Ridge Drive, Chino Hills, CA 91709, USA.
Clin Chim Acta. 2019 May;492:12-19. doi: 10.1016/j.cca.2019.01.027. Epub 2019 Jan 31.
Cancer remains a major disease process with considerable healthcare and socioeconomic impact worldwide. Unfortunately, standard treatments using chemotherapy often do not effectively control cancer progression or prevent relapse. Over the past decades, the development of targeted therapies has substantially improved outcomes. Recently, immunotherapy has emerged as a new alternative for more effective cancer treatment and may even bring hope of a cure. Cancer immunotherapy functions by reinforcing a patient's immune defense system to fight the disease. Clinically, promising immunotherapy approaches have, however, been limited by unpredictable response and strong adverse effects. A drug delivery system (DDS) that effectively targets tumor and reduces drug exposure to normal tissue would mitigate these limitations. In this regard, nanotechnology has been intensively studied as a DDS for targeting tumors with various oncologic drugs. Several have resulted in improved treatment and outcome. Research has shown that nanoparticle drug delivery technologies can also be applied to immunotherapy. In this review, the current state of nanotechnology will be discussed. Because most cancer immunotherapies approved in recent years are protein drugs, this article will focus on a micellar nanocomplex (MNC) technology, a DDS platform especially suited for targeted delivery of these therapeutics to solid tumors.
癌症仍然是一种主要的疾病过程，在全球范围内对医疗保健和社会经济都有重大影响。不幸的是，使用化疗的标准治疗方法通常不能有效地控制癌症的进展或预防复发。在过去的几十年中，靶向治疗的发展大大改善了治疗效果。最近，免疫疗法已成为治疗癌症的一种新的替代方法，甚至可能带来治愈的希望。癌症免疫疗法通过增强患者的免疫系统来对抗疾病。然而，临床上有前景的免疫疗法方法受到不可预测的反应和强烈的副作用的限制。一种有效的靶向肿瘤并减少药物暴露于正常组织的药物输送系统（DDS）将减轻这些限制。在这方面，纳米技术已被作为用于各种肿瘤药物靶向肿瘤的 DDS 进行了深入研究。其中一些已经导致了治疗和结果的改善。研究表明，纳米颗粒药物输送技术也可应用于免疫疗法。在这篇综述中，将讨论纳米技术的现状。由于近年来批准的大多数癌症免疫疗法都是蛋白质药物，因此本文将重点介绍胶束纳米复合物（MNC）技术，这是一种 DDS 平台，特别适合于将这些治疗药物靶向递送至实体瘤。
